Clinical Research Technology
Clinical Research Technology is recorded as a service provider in 17 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 17 of 17 trials · Latest update first
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)
Sponsor Greenwich LifeSciences Inc.
- Start (EU)
- Latest update
- Estimated end
Prevention of Ribociclib-related hepatotoxicity in breast cancer patients: a phase II, multicentre, open label, single arm trial of Silimarin.
Sponsor Fondazione Oncotech Impresa Sociale
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Phase II, Open-Label, Single-Arm, Multicentre Study of Carboplatin, Paclitaxel, and Tislelizumab in Biomarker-Selected Patients with Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma – PERSEPHONE Trial
Sponsor Fondazione GONO Plus
- Start (EU)
- Latest update
- Estimated end
- Not reported
ImmunotherApy for the Prevention of High-Risk Oral DIsorders malignanT transformation - APHRODITE trial
Sponsor Humanitas Mirasole S.p.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage HepatoCellular Carcinoma
Sponsor Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
- Start (EU)
- Latest update
- Estimated end
A phase II study of Sonidegib in Nevoid Basal Cell Carcinoma Syndrome (Gorlin) syndrome and sporadic BCC patients in EADO stage IIb. SIBLINGS TRIAL
Sponsor Fondazione GONO Plus
- Start (EU)
- Latest update
- Estimated end
- Not reported
Pembrolizumab plus Lenvatinib in vulvar cancer patients: The prospective, multi-cohorts and multicentre, phase 2 MITO VULVA-01 study.
Sponsor IRCCS Istituto Nazionale Tumori Fondazione Pascale
- Start (EU)
- Latest update
- Estimated end
- Not reported
Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population
Sponsor Humanitas Mirasole S.p.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Inavolisib for PIK3CA mutated advanced endometrial cancer:a multicentric, phase II, MITO END-4 trial
Sponsor IRCCS Istituto Nazionale Tumori Fondazione Pascale
- Start (EU)
- Latest update
- Estimated end
- Not reported
Induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC). PRIME H&N study
Sponsor Fondazione GONO Plus
- Start (EU)
- Latest update
- Estimated end
- Not reported
Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS STUDY
Sponsor Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi- centre, 2 parallel arms randomized controlled trial
Sponsor University Of Bari Aldo Moro
- Start (EU)
- Latest update
- Estimated end
- Not reported
Use of LOncastuximab Tesirine in patients with RElapsed/Refractory Diffuse Large B-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) who have progressive disease after CAR T-cell treatment - LORELY
Sponsor Humanitas Mirasole S.p.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZED STUDY
Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Start (EU)
- Latest update
- Estimated end
- Not reported
Monocentric, open-label, single-arm, phase I/II clinical trial to evaluate the use of the ONCOGREEN galenic formulation consisting of indocyanine green (ICG) with autologous extracellular vesicles (EVs) for in vivo diagnostics of solid neoplasms undergoing surgical removal - ONCOGREEN study
Sponsor Universita Degli Studi Di Milano
- Start (EU)
- Latest update
- Estimated end
- Not reported
Early start corticosteroids versus standard care (RASBs followed by corticosteroids) for proteinuria in Immunoglobulin A Nephropathy (IgAN) patients with active renal lesions identified by kidney biopsy and RASBs combined with corticosteroids versus sodium-glucose cotransporter2 inhibitor combined with RASBs for proteinuria and renal function in IgAN patients with chronic renal lesions identified by kidney biopsy. A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY BIOPSY FINDINGS IN IgAN PATIENTS (CLIgAN)
Sponsor Fondazione Schena Centro Europeo Della Ricerca Sulle Malattie Renali
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Effect of metyrapone on cardiovascular risk factors in patients with adrenal incidentalomas and subclinical/mild Cushing's syndrome
Sponsor Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Clinical Research Technology?
The 2026-10-09 snapshot links Clinical Research Technology to 17 distinct CTIS trials. Recorded services include Project management, Safety reporting & pharmacovigilance, Clinical monitoring, Regulatory services, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Clinical Research Technology?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Oral Health and Dentistry, Otolaryngology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Clinical Research Technology conducted?
The linked trials record locations in 11 countries, including Italy, Austria, Germany, Spain, France. These are trial locations, not confirmed office locations or countries where Clinical Research Technology delivered services.
What can this page tell me about Clinical Research Technology's trial experience?
Browse 17 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Clinical Research Technology. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Clinical Research Technology S.r.l.